BioInvent International AB (publ) (STO: BINV)
Sweden
· Delayed Price · Currency is SEK
46.25
-1.25 (-2.63%)
Nov 19, 2024, 5:29 PM CET
BINV Revenue
BioInvent International AB had revenue of 12.76M SEK in the quarter ending September 30, 2024, a decrease of -52.37%. This brings the company's revenue in the last twelve months to 38.64M, down -49.68% year-over-year. In the year 2023, BioInvent International AB had annual revenue of 71.46M, down -78.09%.
Revenue (ttm)
38.64M
Revenue Growth
-49.68%
P/S Ratio
77.81
Revenue / Employee
335.97K
Employees
111
Market Cap
3.00B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 71.46M | -254.67M | -78.09% |
Dec 31, 2022 | 326.13M | 306.74M | 1,582.45% |
Dec 31, 2021 | 19.38M | -127.99M | -86.85% |
Dec 31, 2020 | 147.37M | 53.63M | 57.21% |
Dec 31, 2019 | 93.74M | 55.19M | 143.18% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca PLC | 519.35B |
Swedish Orphan Biovitrum AB (publ) | 25.44B |
Sectra AB (publ) | 3.17B |
Getinge AB (publ) | 33.59B |
Camurus AB (publ) | 1.69B |
Vitrolife AB (publ) | 3.56B |
Medicover AB (publ) | 22.60B |
Elekta AB (publ) | 18.12B |
BioInvent International AB News
- 2 months ago - Transgene and BioInvent's Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments - Benzinga